Is Nurix Therapeutics Stock a Good Investment?
Nurix Therapeutics Investment Advice | NRIX |
- Examine Nurix Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Nurix Therapeutics' leadership team and their track record. Good management can help Nurix Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Nurix Therapeutics' business and its evolving consumer preferences.
- Compare Nurix Therapeutics' performance and market position to its competitors. Analyze how Nurix Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Nurix Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Nurix Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Nurix Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Nurix Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Nurix Therapeutics Stock
Researching Nurix Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The book value of Nurix Therapeutics was now reported as 5.62. The company recorded a loss per share of 2.9. Nurix Therapeutics had not issued any dividends in recent years.
To determine if Nurix Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nurix Therapeutics' research are outlined below:
| Nurix Therapeutics generated a negative expected return over the last 90 days | |
| Nurix Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (145.87 M). | |
| Nurix Therapeutics currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
Nurix Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nurix Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nurix Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 11th of April 2024 Next Financial Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 31st of August 2023 Last Quarter Report | View | |
| 30th of November 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Nurix Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Nurix Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-07-13 | 2021-05-31 | -0.54 | -0.6 | -0.06 | 11 | ||
2024-07-11 | 2024-05-31 | -0.63 | -0.71 | -0.08 | 12 | ||
2023-10-12 | 2023-08-31 | -0.76 | -0.68 | 0.08 | 10 | ||
2023-02-09 | 2022-11-30 | -0.79 | -0.87 | -0.08 | 10 | ||
2023-07-13 | 2023-05-31 | -0.56 | -0.45 | 0.11 | 19 | ||
2023-04-13 | 2023-02-28 | -0.87 | -0.75 | 0.12 | 13 | ||
2022-01-27 | 2021-11-30 | -0.69 | -0.85 | -0.16 | 23 | ||
2021-04-13 | 2021-02-28 | -0.46 | -0.63 | -0.17 | 36 |
Know Nurix Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nurix Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nurix Therapeutics backward and forwards among themselves. Nurix Therapeutics' institutional investor refers to the entity that pools money to purchase Nurix Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Soleus Capital Management, L.p. | 2024-06-30 | 2.1 M | Commodore Capital Lp | 2024-09-30 | 1.6 M | Citadel Advisors Llc | 2024-09-30 | 1.5 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Driehaus Capital Management Llc | 2024-06-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Candriam Luxembourg S.c.a. | 2024-06-30 | 1.2 M | Deutsche Bank Ag | 2024-06-30 | 1 M | Nuveen Asset Management, Llc | 2024-06-30 | 981.2 K | Blackrock Inc | 2024-06-30 | 6.8 M | Redmile Group, Llc | 2024-09-30 | 4.3 M |
Nurix Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.55 B.Market Cap |
|
Nurix Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.83) | (0.78) |
Determining Nurix Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Nurix Therapeutics is a good buy. For example, gross profit margin measures Nurix Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nurix Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Nurix Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nurix Therapeutics. Check Nurix Therapeutics' Beneish M Score to see the likelihood of Nurix Therapeutics' management manipulating its earnings.
Evaluate Nurix Therapeutics' management efficiency
Nurix Therapeutics has return on total asset (ROA) of (0.2946) % which means that it has lost $0.2946 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5796) %, meaning that it created substantial loss on money invested by shareholders. Nurix Therapeutics' management efficiency ratios could be used to measure how well Nurix Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.49 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, Nurix Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 5.7 M in 2024, whereas Total Assets are likely to drop slightly above 318.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.32 | 4.35 | |
| Tangible Book Value Per Share | 3.32 | 4.38 | |
| Enterprise Value Over EBITDA | (2.00) | (2.10) | |
| Price Book Value Ratio | 1.52 | 1.59 | |
| Enterprise Value Multiple | (2.00) | (2.10) | |
| Price Fair Value | 1.52 | 1.59 | |
| Enterprise Value | 282.6 M | 475.4 M |
The operational strategies employed by Nurix Therapeutics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 2.2 |
Basic technical analysis of Nurix Stock
As of the 26th of November, Nurix Therapeutics secures the Mean Deviation of 2.52, risk adjusted performance of (0.01), and Standard Deviation of 3.52. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nurix Therapeutics, as well as the relationship between them.Nurix Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nurix Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nurix Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nurix Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nurix Therapeutics' Outstanding Corporate Bonds
Nurix Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nurix Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nurix bonds can be classified according to their maturity, which is the date when Nurix Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US67080LAA35 Corp BondUS67080LAA35 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Nurix Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Nurix Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 2.52 | |||
| Coefficient Of Variation | (4,237) | |||
| Standard Deviation | 3.52 | |||
| Variance | 12.4 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 22.77 | |||
| Value At Risk | (4.73) | |||
| Potential Upside | 6.17 | |||
| Skewness | (0.73) | |||
| Kurtosis | 3.68 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 2.52 | |||
| Coefficient Of Variation | (4,237) | |||
| Standard Deviation | 3.52 | |||
| Variance | 12.4 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 22.77 | |||
| Value At Risk | (4.73) | |||
| Potential Upside | 6.17 | |||
| Skewness | (0.73) | |||
| Kurtosis | 3.68 |
Consider Nurix Therapeutics' intraday indicators
Nurix Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nurix Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Nurix Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 4th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify |
Nurix Stock media impact
Far too much social signal, news, headlines, and media speculation about Nurix Therapeutics that are available to investors today. That information is available publicly through Nurix media outlets and privately through word of mouth or via Nurix internal channels. However, regardless of the origin, that massive amount of Nurix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nurix Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nurix Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nurix Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nurix Therapeutics alpha.
Nurix Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Nurix Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Nurix Therapeutics Corporate Management
| Stefani Wolff | COO Devel | Profile | |
| Christine JD | Secretary Officer | Profile | |
| John Kuriyan | Founder Board | Profile | |
| JD Esq | VP Counsel | Profile | |
| Cristiana Guiducci | Senior Research | Profile | |
| Pasit Phiasivongsa | Chief Officer | Profile |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.